USE OF FERRIC CITRATE IN THE TREATMENT OF IRON-DEFICIENCY ANEMIA
Described herein are methods for treating patients with iron-deficiency anemia (IDA), comprising administering ferric citrate to such patients. In certain aspects, the patients treated for iron-deficiency anemia have a gastrointestinal disorder, such as inflammatory bowel disease, inflammatory bowel syndrome, Crohn's disease, microscopic colitis (such as collagenous or lymphocytic colitis), or chemically-induced colitis (e.g., NSAID (nonsteroidal anti-inflammatory drug)-induced colitis). In certain aspects, the patients treated for iron-deficiency anemia have blood loss associated with childbirth, menstruation or infection. In some aspects, the patients treated for iron-deficiency anemia have insufficient dietary intake of iron and/or insufficient absorption of iron.
1 . A method for treating iron deficiency anemia in a human patient, wherein the patient has not been diagnosed with chronic kidney disease, the method comprising orally administering a ferric citrate tablet containing approximately 210 mg of ferric iron to the patient, wherein the ferric citrate in the tablet is a complex of iron (+3), 0.70-0.87 (1, 2, 3-propanetricarboxylic acid, 2-hydroxy-), 1.9-3 (H 2 O).
2 . The method of claim 1 , wherein the patient has a serum ferritin level of between 5 ng/ml to 300 ng/ml.
3 . The method of claim 1 or 2 , wherein the ferric citrate is not administered with food.
4 . A method for treating iron deficiency anemia in a human patient, wherein the patient has not been diagnosed with chronic kidney disease and the patient has a serum ferritin level of between 5 ng/ml to 300 ng/ml, the method comprising orally administering a ferric citrate tablet containing approximately 210 mg of ferric iron to the patient, wherein the ferric citrate in the tablet is a complex of iron (+3), 0.70-0.87 (1, 2, 3-propanetricarboxylic acid, 2-hydroxy-), 1.9-3 (H 2 O).
5 . A method for treating iron deficiency anemia in a human patient, wherein the patient has not been diagnosed with chronic kidney disease and the patient has a serum ferritin level of between 5 ng/ml to 300 ng/ml, the method comprising orally administering a ferric citrate tablet containing approximately 210 mg of ferric iron to the patient, wherein the ferric citrate is not administered within 2 hours of food being ingested by the patient, and wherein the ferric citrate in the tablet is a complex of iron (+3), 0.70-0.87 (1, 2, 3-propanetricarboxylic acid, 2-hydroxy-), 1.9-3 (H 2 O).
6 . The method of any of claims 1 - 5 , wherein the patient has a serum ferritin level of between 5 ng/ml to 250 ng/ml.
7 . The method of any of claims 1 - 5 , wherein the patient has a serum ferritin level of between 5 ng/ml to 150 ng/ml.
8 . The method of any of claims 1 - 5 , wherein the patient has a serum ferritin level of between 5 ng/ml to 100 ng/ml.
9 . The method of any of claims 1 - 5 , wherein the patient has a serum ferritin level of between 5 ng/ml to 75 ng/ml.
10 . The method of any of claims 1 - 5 , wherein the patient has a serum ferritin level of between 5 ng/ml to 50 ng/ml.
11 . The method of any of claims 1 - 5 , wherein the patient has a serum ferritin level of between 5 ng/ml to 25 ng/ml.
12 . The method of any of claims 1 - 5 , wherein the patient has a serum ferritin level of between 5 ng/ml to 15 ng/ml.
13 . The method of any of claims 1 - 5 , wherein the patient has a serum ferritin level of between 5 ng/ml to 10 ng/ml.
14 . A method for treating iron deficiency anemia in a human patient that has not been diagnosed with chronic kidney disease, the method comprising:
(a) orally administering to the patient one ferric citrate tablet containing approximately 210 mg of ferric iron per day, wherein the ferric citrate is not administered within 2 hours of food being ingested by the patient, and wherein the ferric citrate in the tablet is a complex of iron (+3), 0.70-0.87 (1, 2, 3-propanetricarboxylic acid, 2-hydroxy-), 1.9-3 (H 2 O); and
(b) decreasing the dose of ferric citrate after 4 weeks if the hemoglobin concentration of the subject has increased by more than 5 g/dl and increasing the dose of ferric citrate after 4 weeks if the hemoglobin concentration of the subject has increased by less than 1 g/dl.
15 . The method of any one of claims 1 - 14 , wherein the patient has a gastrointestinal disorder.
16 . The method of claim 15 , wherein the gastrointestinal disorder is inflammatory bowel disease, inflammatory bowel syndrome, Crohn's disease, ulcerative colitis, microscopic colitis, or chemically-induced colitis.
17 . The method of claim 16 , wherein the microscopic colitis is collagenous colitis or lymphocytic colitis.
18 . The method of claim 16 , wherein the chemically-induced colitis is NSAID (nonsteroidal anti-inflammatory drug)-induced colitis.
19 . The method of any one of claims 1 - 14 , wherein the patient has blood loss.
20 . The method of claim 19 , wherein the blood loss is associated with childbirth or menstruation.
21 . The method of claim 19 , wherein the blood loss is associated with an infection.
22 . The method of any one of claims 1 - 14 , wherein the patient has insufficient dietary intake of iron.
23 . The method of any one of claims 1 - 14 , wherein the patient has insufficient absorption of iron.
24 . The method of any one of claims 1 - 23 , wherein the patient is monitored for one or more iron storage parameters.
25 . The method of claim 24 , wherein the one or more iron storage parameters is selected from the group consisting of hemoglobin concentration, serum ferritin level, TSAT value, serum iron level, hematocrit level, TIBC value, plasma erythropoietin level, and FEP level.